On the stock market since 2004, it operates in the world of health and science. It has 31 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 16% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $4.3M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly above the class average — a step short of the very top.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 65% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 23% a year on average.
There is $5.4M in the vault; even if every debt were paid off, $4.3M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 40/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, NEPH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NEPH is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.